Upfront Briefing
Novo Nordisk picked up an FDA approval for Awiqli, positioning once-weekly basal insulin against the daily incumbents (and giving every payer committee another dosing schedule to argue about).
Elsewhere: Novartis agreed to buy Excellergy for a Phase 1 next-gen anti-IgE swing, and Rocket landed an FDA gene-therapy approval that shifts the investor debate from “will it” to “can they launch it.”
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,477.2 |
(1.7%) |
(5.6%) |
| Nasdaq 100 |
23,587.0 |
(2.4%) |
(6.4%) |
| Russell 2000 |
2,493.3 |
(1.7%) |
(0.6%) |
| Healthcare (XLV) |
145.7 |
(0.3%) |
(5.9%) |
| Biotech (XBI) |
123.9 |
0.0% |
+2.0% |
| Nasdaq Biotech (NBI) |
5,716.6 |
(0.2%) |
+0.2% |
| Clinical Trials (BBC) |
41.2 |
+0.5% |
+9.4% |
|
- Risk-off tape: the Nasdaq 100 (2.4%) led the selloff as rising oil, higher Treasury yields, and renewed Iran-war uncertainty hit long-duration tech hardest, while biotech held up relatively better (XBI 0.0%, NBI (0.2%)).
- Relative resilience: healthcare (XLV) slipped just (0.3%) and Clinical Trials (BBC) rose +0.5%, suggesting investors were de-risking index beta more than indiscriminately selling biotech-specific risk.
- Market data: U.S. close Thu 26-Mar-2026.
The Big 3
|
1
|
Novartis agrees to acquire Excellergy, Inc.
|
- Novartis agreed to acquire Excellergy, Inc., adding a Phase 1 next-generation anti-IgE asset. The deal builds on Novartis’ allergy leadership and could shape competition in IgE-driven diseases.
- Why it matters: The asset angle matters here: Novartis is buying into an early next-generation anti-IgE program aimed at food allergy, where the commercial prize is not just efficacy but cleaner positioning on dosing, convenience, and breadth of allergen coverage. For investors, that reinforces how valuable differentiated anti-IgE assets can be even at Phase 1 if they plausibly extend the category beyond today’s incumbent profiles.
- Source: PR
|
|
2
|
FDA approves Novo Nordisk’s once-weekly basal insulin
|
- The FDA approved Novo Nordisk’s Awiqli for adults with type 2 diabetes. The once-weekly dosing could support uptake and lifecycle expansion in basal insulin versus daily regimens.
- Why it matters: Weekly basal insulin gives Novo a differentiated adherence and convenience pitch in a mature category, which matters for formulary positioning as much as efficacy. For investors, the question now shifts from approval risk to 2H26 launch execution and whether once-weekly dosing can expand the commercial ceiling of basal insulin versus daily incumbents.
- Source: Reuters
- More: Company PR
|
3 | FDA approves Rocket gene therapy for rare immune disorder |
- The FDA approved a Rocket gene therapy for a rare immune disorder. The decision can de-risk commercialization and set a regulatory benchmark for Rocket’s gene therapy platform in rare immunology.
- Why it matters: Approval moves Rocket out of binary regulatory risk and into the harder commercial phase, but it also creates an immediate balance-sheet read-through via the Rare Pediatric Disease Priority Review Voucher. For investors, the story is now a mix of launch execution, manufacturing reliability, reimbursement in an ultra-rare setting, and how much value the platform-plus-PRV package can support.
- Source: STAT
- More: FDA
|
Everything Else that broke
- AstraZeneca says tozorakimab hit primary endpoints in two Phase 3 COPD trials. — Reuters
- Wave loses half its market cap on obesity data. — BioCentury
- Kodiak Phase 3 data support VEGF conjugate in retinopathy. — BioCentury
- Bavarian Nordic files to extend mpox vaccine to ages 2–11. — PR
- Disc Medicine completes Phase 3 APOLLO enrollment for bitopertin. — PR
- EMA validates taletrectinib MAA for ROS1+ NSCLC, Eisai says. — PR
- DBV Technologies reports full-year 2025 results and update. — PR
- LeonaBio reports full-year 2025 results and business update. — PR
- Zentalis reports full-year 2025 results and operational updates. — PR
- SpyGlass Pharma reports Q4 and full-year 2025 results. — PR
- LB Pharmaceuticals reports full-year 2025 results, update. — PR
- Vivani Medical reports full-year 2025 results, update. — PR
- IMDX submits GraftAssureDx for FDA review; reports Q4. — PR
- Akeso reports full-year 2025 financial results. — PR
- Beyond Air CEO resigns; Robert Goodman appointed CEO. — PR
- HHS official pitches taking on China biotech. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly
|
M&A / BD&L
-
Novartis agrees to acquire Excellergy, Inc. — PR
VC / Private Financings
- Pinnacle Medicines raised an oversubscribed $89M Series B to push oral peptide therapeutics into the clinic — a financing around the idea that peptide-class efficacy need not stay trapped in injectable formulations; syndicate was co-led by LAV and Foresite Capital, joined by Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investor OrbiMed. — PR
IPOs / Follow-Ons
- Zenas BioPharma priced concurrent public offerings totaling $300.0M gross proceeds, split between $200.0M of 2.50% convertible senior notes due 2032 and $100.0M of common stock. — PR
Things that make you go hmmm ...
Worth a look: Wave’s INLIGHT trial slides help explain why the stock traded so badly on the update — not just whether the study hit, but how investors interpreted the magnitude and profile of the obesity signal.
Source: Wave.
Presentation
Academic Corner - Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet
- Oral macrocyclic IL-23 inhibitor nabs FDA approval for psoriasis. — Nature RDD
- Clinical Implications of Minipuberty. — NEJM
|
